Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals’ director buys 2,000 shares at $23.51, signaling insider confidence amid volatile pricing and a focus on liver‑disease therapeutics.

Insider buying at Mirum Pharmaceuticals signals confidence in its liver‑therapy pipeline; CFO’s recent trades hint at future upside.

Mirum Pharmaceuticals insider trades reveal CMO’s confidence in Phase III liver‑disease therapy, blending stock purchases with tax‑smart PRU sales for strategic gains.

CEO insider buying at Mirum Pharmaceuticals signals confidence in its liver‑therapy pipeline—read the trade analysis for insights on liquidity, dilution, and market impact.

Mirum Pharmaceuticals’ COO buys shares, signaling confidence amid FDA approval of Mira‑B and a promising pipeline—watch insider moves, clinical milestones, and market trends.

Mirum Pharmaceuticals’ CEO insider trades reveal a balanced strategy, not a confidence hit—focus on its niche liver drug, payer deals, and digital tech for growth insights.

Explore insider moves at Mirum Pharmaceuticals, the impact on its biopharma pipeline, regulatory hurdles, and growth prospects – a deep dive for investors.

Mirum Pharma’s insider grants reveal leadership’s confidence in liver‑disease pipeline and a potential price rebound, but investors should watch earnings and regulatory milestones.

Radovich Peter’s recent buy of 5,750 Mirum shares signals executive confidence amid a strong earnings beat, sparking a bullish outlook for investors.

Mirum Pharmaceuticals insider buy signals confidence amid 104% year‑to‑date rally and growing liver‑disease pipeline—what it means for investors.